Plain-English translation of NCT05381194 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a treatment called BPaL(M)—a combination of three medications (bedaquiline, pretomanid, linezolid, and sometimes moxifloxacin) for patients with drug-resistant tuberculosis. Drug-resistant TB is a serious form of the disease that doesn't respond to the usual TB medications. Earlier research in other countries showed this medication combination worked well, and this study will see if it works equally well for Korean patients.
Some tuberculosis infections have become resistant to the standard first-line antibiotics, making them much harder to treat and requiring longer treatment with more side effects. This medication combination has shown promise in other studies, and researchers want to confirm it's effective and safe specifically for Korean patients with this challenging form of TB.
You likely qualify if…
You likely don't qualify if…
You would take the medication combination for 6 months as part of the study. During this time, you would have regular visits to the clinic for check-ups, blood tests, heart monitoring (EKG), and imaging to see how well the treatment is working and to watch for any side effects. The study team will track how you respond to the medication throughout the 6-month treatment period.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea
Phase
Post-approval monitoring
Sponsor
Asan Medical Center
Collaborators
Pusan National University Hospital, Samsung Medical Center
Enrollment target
~80 participants
Started
December 2022
Primary completion
December 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tae Sun Shim, MD, PhD
Asan Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.